1. Noninjection routes for immunotherapy
Giorgio Walter Canonica, MD, Giovanni Passalacqua, MD 
Journal of Allergy and Clinical Immunology 
Volume 111, Issue 3, Pages (March 2003)
DOI: /mai
Copyright © 2003 Mosby, Inc. Terms and Conditions

2. Fig. 1
The chronology of the different modalities of immunotherapy. RCTs , Randomized controlled trials.
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2003 Mosby, Inc. Terms and Conditions

3. Fig. 2
Plasma pharmacokinetics (chromatography) of a 123I-radiolabeled Par j 1 monomeric allergoid after sublingual administration. A small peak of the intact protein can be evidenced in the plasma of the 2 patients. The chromatographic profile of the native radiolabeled specimen (before administration) is plotted in red (from reference 124).
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2003 Mosby, Inc. Terms and Conditions

4. Fig. 3
The dose-response relationship with SLIT. Efficacy has been shown for doses ranging between 20 and 375 times those of SCIT. Gastrointestinal side effects increase when the dosage rises.
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2003 Mosby, Inc. Terms and Conditions

5. Fig. 4
Number of patients with and without asthma, at baseline, at the end of the 5-year SLIT course, and 5 years after SLIT discontinuation. Significant intragroup and intergroup P values are indicated on the bars (from reference 123 ).
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2003 Mosby, Inc. Terms and Conditions